{"url":"https://newsforagent.com/news/2026-11-14/cvs-health-glp1-break-even-price","markdown_url":"https://newsforagent.com/news/2026-11-14/cvs-health-glp1-break-even-price.md","title":"CVS Health Says GLP-1 Drugs Break Even Below $350 a Month","headline":"CVS Health Ties GLP-1 Break-Even to $350 Monthly Price in Aetna Claims Analysis","description":"CVS Health says GLP-1 drugs break even for plan sponsors below $350 a month, as Aetna claims show 10-12% fewer ER visits in the first two years of use.","section":"Research & Clinical Trials","published_at":"2026-11-14T11:42:02+00:00","modified_at":"2026-11-14T11:42:02+00:00","author":"News Desk","key_takeaways":["CVS Health said employers and health plan sponsors break even on GLP-1 drugs priced below $350 per month.","An analysis of Aetna claims found 10-12% lower emergency room visits in the first and second year of GLP-1 use.","About 14% of companies have dropped or plan to drop GLP-1 coverage in 2027, as premiums are expected to rise over 9%."],"companies":[{"name":"CVS Health","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00000bk/cvs-health","website":"https://www.cvshealth.com"},{"name":"Eli Lilly","is_primary":false,"profile_url":"https://akta.pro/company-profiles/00000ap/eli-lilly","website":"https://www.lilly.com"},{"name":"Novo Nordisk","is_primary":false,"profile_url":"https://akta.pro/company-profiles/00000i2/novo-nordisk","website":"https://www.novonordisk.com"}],"source":{"publisher":"Yahoo","title":"CVS says GLP-1s save money when priced below $350 per month","url":"https://finance.yahoo.com/healthcare/articles/cvs-says-glp-1s-save-110514978.html"},"other_sources":[],"tags":["Research & Clinical Trials","CVS Health","Eli Lilly","Novo Nordisk"],"body_markdown":"CVS Health said employers and health plan sponsors could break even on GLP-1 drugs if they are priced below $350 per month, because lower spending on hospitalizations and emergency room visits offsets the drug costs. [Yahoo](https://finance.yahoo.com/healthcare/articles/cvs-says-glp-1s-save-110514978.html) reported the finding on November 14.\n\n## CVS Health's Aetna Claims Analysis\n\n[CVS Health](https://akta.pro/company-profiles/00000bk/cvs-health) is a vertically integrated U.S. healthcare company that runs the largest retail pharmacy chain, the CVS Caremark pharmacy benefit manager and the Aetna health insurance business, according to [company records](https://akta.pro/company-data). The analysis drew on Aetna insurance claims for patients newly taking GLP-1 medicines from [Eli Lilly](https://akta.pro/company-profiles/00000ap/eli-lilly) and [Novo Nordisk](https://akta.pro/company-profiles/00000i2/novo-nordisk), compared with similar patients not taking the drugs.\n\nThe drugs included Mounjaro and Ozempic for diabetes and Zepbound and Wegovy for obesity. The analysis covered periods of up to three years, with patients starting the medicines between 2023 and 2025, and it did not break out figures for obesity patients alone. CVS said current prices add to spending because they are too high for lower medical costs to offset them.\n\nDr Amy Compton-Phillips, chief medical officer at CVS Health, said the drugmakers' direct-to-consumer prices suggest they can still profit by charging less than $350 a month. \"I hope that we can reach that price sooner rather than later,\" she said in an interview ahead of the HLTH USA conference in Las Vegas, where CVS will present the findings on November 15.\n\n## What CVS Health Found on Emergency Visits\n\nCVS said GLP-1 use for obesity, diabetes or other conditions was associated with 10-12% lower emergency room visits in the first and second year of use. It examined records for 60,000 people during the first year and 20,000 people for a second year. Zepbound and Wegovy can cost about $299 and $349 for cash-pay customers, while employers and other health plan sponsors pay between $617 and $766 monthly for the drugs, according to a 2025 study by the Employee Benefit Research Institute. CVS declined to comment on the average prices paid.\n\n## CVS Health's GLP-1 Access Program\n\nIn June 2026, CVS Health launched a GLP-1 Support Program with Walmart and Novo Nordisk's NovoCare, extending weight-loss medication access through CVS Pharmacy, CVS Caremark and Aetna with monthly copays as low as $25-$149 depending on coverage, according to akta.pro company records. The company reported $100.4 billion in first-quarter 2026 revenue, up 6.2% year over year, and raised its full-year 2026 earnings guidance to $7.30-$7.50 per share.\n\n## CVS Health's Split and Rating Review\n\nOn November 4, 2026, CVS Health announced a plan to split into CVS Health and CVS Pharmacy, expected to complete in the first half of 2028, [Stock Titan](https://akta.pro/news-signals) reported. AM Best then placed Aetna Life Insurance Company and CVS Caremark Indemnity Ltd. ratings under review with developing implications, according to the same report. On November 7, 2026, Mark Cuban criticized the split as a shareholder play that changes nothing for patients, Yahoo reported.\n\n## What Comes Next for GLP-1 Pricing\n\nCVS will present the findings at HLTH USA on November 15. The US government agreed with Lilly and Novo last year to pay $245 per month for injectable GLP-1 weight-loss drugs in an 18-month pilot testing their cost-effectiveness for Medicare beneficiaries aged 65 and older or with disabilities.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}